[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-of-upper-limb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-of-upper-limb":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,81,108,137,167],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":35,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053937",false,"NCT05142800","Screening For BCRL In Targeted Therapy For Breast Cancer","Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer","Inclusion Criteria:\n\n* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF\u002FHCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.\n* Subjects that will be eligible for the study include:\n* Females between 18 and 80 years of age\n* With a history of breast cancer\n* 4 weeks or more post-surgery\n* With or without edema\n* Undergoing treatment with targeted therapy for early or metastatic disease.\n\nExclusion Criteria:\n\n\\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).","FEMALE","18 Years","80 Years",{"count":19,"type":20},261,"ESTIMATED","OBSERVATIONAL","This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.\n\nA Perometer and Sozo devise will be used to measure volume changes",[24,25,26,27,28,29,30,31,32,33,34],"Lymphedema","Lymphedema Arm","Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema of the Hands","Edema","Edema Arm","Breast Cancer Lymphedema","Breast Cancer Metastatic","Breast Cancer Stage","Breast Cancer",[24,25,26,27,28,29,30,31,32,33,34],"RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2018-12-13",{"date":44,"type":20},"2026-09-30",{"name":46,"class":47},"Massachusetts General Hospital","OTHER",1,{"id":50,"slug":4,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":55,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100522417","NCT06082349","The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema","Effectiveness and Cost-effectiveness of Lymphaticovenous Anastomosis for Cancer Patients Who Suffer From Chronic Peripheral Lymphedema: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Treated for cancer and underwent treatment of either axillary or inguinal lymph nodes or radiotherapy;\n* Early stage lymphedema (ISL I-II) in the upper or lower extremity, and diagnosed by lymphoscintigraphy for the lower extremity;\n* Unilateral lymphedema;\n* Viable lymphatic vessels as determined by indocyanine green (ICG)Lymphography (stage II-III);\n* Refractory lymphedema that underwent at least three months of conservative treatment;\n* Informed consent.\n\nExclusion Criteria:\n\n* History of lymphatic reconstruction in the past 10 years;\n* Late-stage lymphedema of the extremity (ISL classification ≥ II lymphedema) with evident fat deposition and\u002For fibrosis;\n* Patients with active distant metastases, treated with palliative intent;\n* Patients with the active treatment of primary cancer, i.e. surgery, radiotherapy, and\u002For chemotherapy. Note: patients receiving adjuvant targeted and\u002For endocrine treatment are eligible;\n* Edema due to venous insufficiency, evaluated by venous duplex ultrasound of the deep and superficial venous system;\n* Active infection in the lymphedematous extremity;\n* Bilateral lymphedema;\n* Lymphedema present in genital or breast area only;\n* Primary lymphedema;\n* Non-viable lymphatic system as determined by ICG Lymphography (stages IV and V).","ALL",{"count":57,"type":20},110,"INTERVENTIONAL",[60],"NA","The goal of this randomized controlled trial is to compare the effectiveness and cost-effectiveness of lymphaticovenous anastomosis (LVA) with sham surgery for patients suffering from unilateral cancer-related lymphedema in either the upper or lower extremity. It aims to answer whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score.\n\nA total of 110 participants will be allocated randomly into two groups at a 1:1 ratio. The first group will receive lymphaticovenous anastomosis (LVA), while the second group will undergo sham surgery.",[63,27,64,25,65],"Lymphedema, Secondary","Lymphedema, Lower Limb","Lymphedema of Leg",[67,68,69,70],"Lymphaticovenous anastomosis","Sham surgery","Microsurgery","LVA","2026-01-15",{"date":73,"type":40},"2026-01-16",{"date":75,"type":40},"2023-12-18",{"date":77,"type":20},"2029-03-01",{"name":79,"class":47},"Maastricht University Medical Center",3,{"id":82,"slug":4,"hasResults":10,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":58,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100536437","NCT06264817","Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema.","A Multicenter, Single-blinded, Randomized Controlled Study to Assess the Efficacy of Auto-Adjustable MOBIDERL Autofit Armsleeve in the Management of Upper Limb Lymphedema. (LyberT)","LyberT","Inclusion Criteria:\n\n* Unilateral secondary upper limb lymphedema of stage II or III according to the criteria defined by the International Society of Lymphology, following breast cancer\n* Volume difference between affected and healthy arm ≥ 10%\n* Affected arm that fits with one of the 6 standard sizes of the Auto- Adjustable MOBIDERM Autofit armsleeve provided.\n* Signed informed consent prior to any study-mandated procedure.\n\nExclusion Criteria:\n\n* Stage I lymphedema or located in several places.\n* Patients for whom compression is contraindicated.\n* Lymphedema associated with active cancer needing acute chemotherapy or having recurrence or metastasis.\n* Motor and sensitive neurological deficiency \u002F psychiatric or addictive disorders\n* Pregnant or breastfeeding patient\n* Patient intolerant to MOBIDERM Autofit or known allergies to the components used.\n* Participation to any other clinical study which has an impact on the different endpoints\n* Vulnerable patient, adults being the object of a legal protective measure or enable to express their consent.",{"count":89,"type":20},40,[60],"This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess compared to the compression bandages to manage the volume of upper limb lymphedema in patients with breast cancer related lymphedema",[27],[94,95,96],"Lymphedema of upper limb","Compression garments","lymphedema management","2024-09-20",{"date":99,"type":40},"2024-09-23",{"date":101,"type":40},"2024-03-15",{"date":103,"type":20},"2025-04-15",{"name":105,"class":106},"Thuasne","INDUSTRY",2,{"id":109,"slug":4,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":58,"phases":116,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":48},"100557041","NCT06532955","The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema","Pilot Study on Robotic Assisted Microsurgical Lymphatico-venular Anastomosis","Inclusion Criteria:\n\n* Female gender;\n* Treated for primary early stage breast cancer;\n* Early stage lymphedema of the arm (stage 1 or 2 on ISL classification);\n* ELV \\> 10%;\n* Suffering from unilateral disease.\n\nExclusion Criteria:\n\n* Male gender;\n* Stage 3 lymphedema of the arm;\n* Receiving current breast cancer treatment;\n* Distant breast cancer metastases;\n* Current substance abuse;\n* History of marcaine or indocyanine green allergy;\n* Non-viable lymphatic system as determined by near infrared imaging;\n* Previous LVA (\\\u003C10 years) in the arm with lymphedema.",{"count":115,"type":20},60,[60],"This study assesses the performance of robot-assisted microsurgery. Lymphaticovenous anastomosis (LVA) is the most difficult procedure in microsurgery at this moment. The LVA technique is applied to treat for example breast cancer-related lymphedema (BCRL). Therefore, this LVA procedure is compared using a manual expert and the same expert applying robot-assisted LVA.",[24,25,26,27,119,63,120,121,122],"Lymphedema; Surgical","Lymphedema of Limb","Lymphedema, Breast Cancer","Lymphedema, Non-Filarial",[124,69,125,126,127,67,128,70],"Robot-assisted microsurgery","Robot","Robotic-assisted","Robot-assisted","Lymphatico-venular anastomosis","2024-07-30",{"date":131,"type":40},"2024-08-01",{"date":133,"type":40},"2017-06-01",{"date":135,"type":20},"2026-01-01",{"name":79,"class":47},{"id":138,"slug":4,"hasResults":10,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":58,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100524814","NCT06113627","Lymphatic Response to Resistance Exercise in Breast Cancer Survivors","Prevention-Related Lymphatic Response to Resistance Exercise in Breast Cancer Survivors at Risk of Breast Cancer-Related Lymphedema","LinfoGYM","Inclusion Criteria:\n\n* Women diagnosed with breast cancer\n* Being of legal age\n* Histologically confirmed primary Breast Cancer (I-IIIA) (without the presence of metastasis) with a diagnosis in the last year\n* Unilateral involvement\n* Surgery for the tumor at least 6 weeks before the start of the intervention\n* WHO performance status of 0 (asymptomatic, complete and ambulatory activity)\n* Correct understanding of Spanish\n* Approval by signing the informed consent;\n* Mus be considered at risk for developing LACM: 1) Have undergone surgery that includes axillary dissection; 2) Have received or are undergoing regional lymph node radiation; 3) BMI \\>30 kg\u002Fm2. . These patients are considered to have stage 0, subclinical or latent according to the International Society of Lymphology (ISL) , since they will not present signs or symptoms, but lymphatic transport will be altered by the treatments themselves\n\nExclusion Criteria:\n\n* Women already diagnosed with LACM in stage I, II or III according to the ISL or if they present an L-Dex ratio \\> 10 or a difference in volume equal to or greater than 10% between both extremities\n* Suffer from or have been diagnosed with any other lymphatic-venous disease in the upper extremity, such as venous insufficiency, thrombosis or lipedema;\n* Suffer from conditions that prevent resistance exercise of the upper body\n* Participation in regular (\\>1 time\u002Fweek) and intense exercises involving the upper extremity during the last month\n* Suffer from heart disease\n* Inability to complete questionnaires;\n* A physical condition that prevents them from making hospital visits\n* Taking any drug that may affect the lymphatic and circulatory system, such as diuretics or corticosteroids\n* Women which presents some type of wound or infection on the skin.",{"count":145,"type":20},170,[60],"The objective of this study is 1) to study the acute and chronic effect of resistance therapeutic physical exercise (RTPE) in the prevention of breast cancer-related lymphedema (BCRL) in breast cancer survivors at risk using variables related to the lymphatic response; 2) Study the possible relationship between changes in body composition at a local and regional level and volume changes produced by RTPE in patients at risk of suffering from BCRL.",[31,149,27],"Survivorship",[34,151,31,152,153,154,155,156],"Lymphedema, Early-Onset","Exercise Therapy","Exercise Training","Acute Exercise","Exercise Movement Techniques","Physiotherapy (Techniques)","NOT_YET_RECRUITING","2023-10-30",{"date":160,"type":40},"2023-11-02",{"date":162,"type":20},"2024-08",{"date":164,"type":20},"2027-01-15",{"name":166,"class":47},"University of Malaga",{"id":168,"slug":4,"hasResults":10,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":173,"sex":55,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100501083","NCT05804643","Novel MRI Techniques on Evaluation of Lymphedema","Development and Optimization of Novel MRI Techniques on Evaluation of Therapeutic Effects for Lymphedema Secondary to Breast Cancer Treatment: An Integrated Study of Pre-clinical Animal Models and Clinical Follow-up","Inclusion Criteria:\n\n* adults with breast cancer related lymphedema\n\nExclusion Criteria:\n\n* children younger than 20 years old\n* pregnancy\n* patients who have absolute contraindications regarding MRI scanning:\n\n  1. The cardiac implantable electronic device (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.\n  2. Metallic intraocular foreign bodies.\n  3. Implantable neurostimulation systems\n  4. Cochlear implants\u002Fear implant: bone-anchored hearing aid (BAHA) cochlear implant type can be scanned on a 1.5-tesla scanner only after the patient removes the battery. Cochlear implant wrapping scheduling must take place before the patient's MRI appointment.\n  5. Drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps): If possible, the patient has to remove the device.\n  6. Catheters with metallic components (Swan-Ganz catheter)\n  7. Metallic fragments such as bullets, shotgun pellets, and metal shrapnel\n  8. Cerebral artery aneurysm clips\n  9. Magnetic dental implants\n  10. Tissue expander\n  11. Artificial limb\n  12. Hearing aid",true,"20 Years",{"count":176,"type":20},210,"In this project, the investigators aim to investigate the imaging approaches for breast cancer-related secondary lymphedema. The clinical study aims to optimize the conventional MRI methods for mapping lymphedema and assess the post-surgical therapeutic effects in longitudinal follow-up studies. Additionally, a normal imaging database of lymphedema MRI images will be established for future reference. For pre-clinical animal study, investigators aim to develop and integrate two novel MRI methods, including free water elimination diffusion MRI and diffusion kurtosis MRI techniques. By integrating clinical and pre-clinical studies, the investigators aim to establish a precise imaging tool for evaluating the therapeutic effects of lymphedema for following translational applications.",[27],[24,180,181,182,183],"supermicrosurgical technique","axillary procedures","pre-clinical animal model","diffusion MRI","2023-04-16",{"date":186,"type":40},"2023-04-19",{"date":188,"type":40},"2023-04-10",{"date":190,"type":20},"2026-12",{"name":192,"class":47},"National Taiwan University Hospital",""]